

## Details of Director's Interest Notices

**Melbourne, Australia, August 26, 2022** – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid and psychedelic medicines and therapies for unmet medical needs, notes the following change in Director's equity interests.

### Mr George Anastassov

An Appendix 3Y – Change of Director's Interest Notice is attached for Mr George Anastassov. Pursuant to the finalisation of the acquisition of APIRx Pharmaceuticals USA, LLC, shares were issued to Mr Anastassov on 05 August 2022, due to a minor administrative oversight the Appendix 3Y was not lodged within the required timeframe.

The Company confirms that it has the required procedures to ensure timely reporting of changes in directors' interests.

**This announcement has been approved for release by Mr Madhukar Bhalla, Company Secretary of Incannex Healthcare Limited.**

### About Incannex Healthcare Limited

Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.

U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.

Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 29 pending patents. Incannex is listed on the Australian Stock Exchange (ASX) with stock code "IHL" and also has American Depository Shares listed on NASDAQ under code "IXHL".

**Website:** [www.incannex.com.au](http://www.incannex.com.au)

**Investors:** [investors@incannex.com.au](mailto:investors@incannex.com.au)



Date: August 26, 2022  
Public Announcement (NASDAQ: IXHL) (ASX: IHL)

### **Forward-looking statements**

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates, as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change. Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date after the date of this press release.

### **Contact Information**

#### **Incannex Healthcare Limited**

Mr Joel Latham  
Managing Director and Chief Executive Officer  
+61 409 840 786  
[joel@incannex.com.au](mailto:joel@incannex.com.au)

#### **Investor Relations Contact – United States**

Alyssa Factor  
Edison Group  
+1 (860) 573 9637  
[afactor@edisongroup.com](mailto:afactor@edisongroup.com)

# Appendix 3Y

## Change of Director's Interest Notice

<b>Name of entity</b>	<b>Incannex Healthcare Limited</b>
<b>ACN</b>	<b>93 096 635 246</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	George Anastassov
<b>Date of last notice</b>	29 June 2022

### Part 1 - Change of director's relevant interests in securities

<b>Direct or indirect interest</b>	Direct
<b>Date of change</b>	05 August 2022
<b>No. and class of securities held prior to change</b>	<ul style="list-style-type: none"> <li>=NIL=</li> </ul>
<b>Number and class of securities acquired</b>	<ul style="list-style-type: none"> <li>66,972,077 IHL ordinary shares (Escrowed to 04 August 2023)</li> </ul>
<b>Number and class of securities disposed</b>	<ul style="list-style-type: none"> <li>Nil</li> </ul>
<b>Value/<del>Consideration</del></b>	<ul style="list-style-type: none"> <li>38,174,083.00</li> </ul>
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>66,972,077 IHL ordinary shares (Escrowed to 04 August 2023)</li> </ul>
<b>Nature of change</b>	<ul style="list-style-type: none"> <li>Shares issued to complete the acquisition of APIRx Pharmaceuticals USA, LLC as approved by the shareholders on 09 June 2022.</li> </ul>

### Part 2 – Change of director's interests in contracts

Not Applicable

### Part 3 – Closed period

<b>Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/a
<b>If prior written clearance was provided, on what date was this provided?</b>	N/a